Similar companies
| Company | Revenue | |
|---|---|---|
 |
Alzamend NeuroALZN |
0 0% |
 |
enGenesENGN |
10,000 0% |
Income Statement (NONE)
| Q4 '24 | QoQ | |
|---|---|---|
| Revenue | 6.1M | 16.4% |
| Gross Profit | 3.4M | 45.9% |
| Cost of Revenue | 2.7M | 7.5% |
| Operating expense | 5.7M | 140.4% |
| Net Income | -2.6M | 36.2% |
| EBITDA | -1.4M | 57.5% |
Balance Sheet (NONE)
| Q4 '24 | QoQ | |
|---|---|---|
| Total Assets | 60M | 1.1% |
| Total Liabilities | 27M | 3.2% |
| Total Equity | 33M | 0.5% |
| Shares Outstanding | 28M | 3.7% |
Cash Flow (NONE)
| Q4 '24 | QoQ | |
|---|---|---|
| Cash from operations | -2M | 11.5% |
| Cash from financing | 2.1M | 23.3% |
Financial Highlights for Immunoprecise Antibodies in Q4 '24
Immunoprecise Antibodies reported a revenue of 6.1M, which is a 16.4% change from the previous quarter. An increase in revenue typically indicates growing demand for the company's products or services. This positive change in revenue is a good sign, suggesting that the company's sales are moving in the right direction.
Gross Profit stood at 3.4M, marking a 45.9% change since the last quarter. Gross profit showcases the efficiency in production and sales processes.
Cost of Revenue was 2.7M, a -7.5% difference from the previous quarter. A rising cost of revenue may suggest increased production or sales costs, which can impact margins. However, if accompanied by a proportionate rise in revenue, it could indicate scaling operations.
Operating Expenses for this period were 5.7M, showing a 140.4% change from the last quarter. Operating expenses cover the costs of running daily business operations. A significant increase might indicate inefficiencies or investments in growth, while a decrease could suggest cost-saving measures or potential underinvestment in key areas.
Net Income for the quarter was -2.6M, showing a 36.2% change from the prior quarter. Net income provides a clear picture of the company's profitability after all expenses. An increase suggests the company is becoming more profitable, while a decrease may raise concerns about the company's financial health, unless there are specific one-time costs or investments.
The company's EBITDA for the quarter was -1.4M, showing a 57.5% change from the previous period. EBITDA gives insight into the company's operational profitability, excluding non-operating expenses like interest and taxes. A rising EBITDA indicates strong operational performance, while a declining EBITDA may signal operational challenges or increased costs.
It was a positive quarter for Immunoprecise Antibodies with growth in revenue, gross profit, and net income. Higher operating expenses might indicate increased investments or potential inefficiencies.
